These data support previous findings showing the same combination had greater antitumor immune effect.39 In contrast, targeting the adenosine pathway with Adoi in 2838c3 allografts where necrosis and consequently peri-necrotic adenosine are low, and M2 macrophages express lower level of Adora2a, did not translate into tumor growth reduction (online supplemental figure 7C). Here, ADORA2A is linked to neoplasm.